A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

clinical trial

Details

Instance of: clinical trial
Start time: April 2019
End time: November 2021
Country: United States
Main subject: non small cell lung cancer recurrent, thyroid cancer, thyroid carcinoma, Breast tumors: composition of microcalcifications, fibrosarcoma, sarcoma
clinical trial phase: phase I clinical trial, phase II clinical trial
maximum age: 21
minimum age: 6
number of participants: 100
research site: Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Cincinnati Children's Hospital Medical Center, Children's Hospital of Philadelphia
short name: LIBRETTO-121
study type: interventional study
title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Nothing in the MetaHistoryBook collection references this item yet.